Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Aromasin is a prescription medicine containing exemestane, an irreversible steroidal aromatase inhibitor. It is approved for postmenopausal women with estrogen receptor-positive early breast cancer after two to three years of tamoxifen and for postmenopausal women with advanced breast cancer that has progressed after tamoxifen treatment. Each tablet contains 25 mg of exemestane.
read more about aromasin ...Exemestane irreversibly inactivates aromatase, the enzyme that converts androgens into estrogens. In postmenopausal women, this action lowers circulating estrogen concentrations and reduces hormonal stimulation of estrogen-dependent breast cancer cells. Exemestane is structurally related to androstenedione and binds irreversibly to the active site of the aromatase enzyme.
Aromasin is approved as adjuvant treatment for postmenopausal women with estrogen receptor-positive early breast cancer after two to three years of tamoxifen, with therapy switched to Aromasin to complete five consecutive years of hormonal treatment. It is also approved for advanced breast cancer in postmenopausal women whose disease has progressed after tamoxifen.
The recommended dose is one 25 mg tablet once daily after a meal. When a strong CYP3A4 inducer such as rifampicin or phenytoin is used at the same time, the labeled Aromasin dose is 50 mg once daily after a meal. Tablets are taken according to the prescribed regimen.
Aromasin can reduce bone mineral density, so bone health is assessed in women with osteoporosis or increased osteoporosis risk. Vitamin D status is checked before aromatase inhibitor treatment. Other concerns include fetal harm and laboratory changes involving cholesterol or liver tests. Systemic estrogen-containing medicines can interfere with Aromasin activity.
Yes. Aromasin contains exemestane, an irreversible steroidal aromatase inhibitor used for selected breast cancers in postmenopausal women.
The recommended dose is one 25 mg tablet once daily after a meal.
Yes. Exemestane can reduce bone mineral density, so bone health is monitored in women with osteoporosis or increased risk.
Yes. Its labeled uses include selected early and advanced breast cancer settings after tamoxifen treatment.
AROMASIN (exemestane) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/020753s025lbl.pdf. Date Accessed September 14, 2026.
DailyMed - AROMASIN (exemestane) tablet. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cf066b7a-032a-416c-8d40-15ba581423e3. Date Accessed September 14, 2026.
Exemestane. MedlinePlus. https://medlineplus.gov/druginfo/meds/a607006.html. Date Accessed September 14, 2026.
Exemestane. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/exemestane. Date Accessed September 14, 2026.
Exemestane. NCI Drug Dictionary. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/exemestane. Date Accessed September 14, 2026.